UK To Speed New COVID-19 Drug Candidates Into Trials
Collaborative Project Hailed As ‘Transformative’
Executive Summary
The first of six new compounds are expected to begin Phase II testing soon as part of the UK’s ACCORD initiative, a randomized platform trial bringing together government, industry and research organisations to find potential treatments for COVID-19.
You may also be interested in...
Coronavirus Update: Moderna Ready For Interim Analysis, Brazil Resumes SinoVac Trial
Moderna's vaccine has reached the requisite number of cases to trigger a Phase III interim analysis and Brazil allows SinoVac's trial to resume after a serious adverse event, but AstraZeneca's Calquence fails to show any benefit in hospitalized COVID-19 patients. Medicago and GSK also report vaccine progress and the RDIF strikes another production deal.
Coronavirus Update: More Drugs Enter Trials, UK To Host Latest Vaccine Summit
In addition to our daily in-depth coverage of key events relating to the coronavirus, we’re bringing you a periodic round-up of other pandemic developments. This edition covers events at the national, European and global level.
AstraZeneca’s COVID-19 Taskforce Starts With Calquence Trial
AstraZeneca will launch a global clinical trial for its blood cancer drug Calquence because it showed early respiratory promise in later-stage COVID-19 patients, those in intensive care units and on ventilators.